DDInter1577 DDInter1676
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer.[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Relugolix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Relugolix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Relugolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Relugolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Relugolix {u} may lead to a major life threatening interaction when taken with {v} Ticagrelor
Relugolix {u} may lead to a major life threatening interaction when taken with {v} Elagolix
Relugolix may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Relugolix may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Relugolix may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Relugolix may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Relugolix may lead to a major life threatening interaction when taken with Ticagrelor
Relugolix may lead to a major life threatening interaction when taken with Elagolix